2023年8月4日 · Low-molecular-weight heparins (LMWHs), for example, dalteparin, enoxaparin, among others, are anticoagulants. These drugs are used in the prophylaxis of venous thromboembolic disease (VTE) on acute or elective admission to the hospital, and they are used in the treatment of deep vein thromboses (DVT) and pulmonary embolism (PE).

Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. [1] They are used in the prevention of blood clots and, in the treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism), and the treatment of myocardial infarction.

2017年9月1日 · In patients with unstable angina or non-Q-wave myocardial infarction, the recommended dose of FRAGMIN Injection is 120 IU/kg of body weight, but not more than 10,000 IU, subcutaneously (s.c.) every 12 hours with concurrent oral aspirin (75 to 165 mg once daily) therapy. Treatment should be continued until the patient is clinically stabilized.

2023年4月3日 · Low Molecular-Weight Heparin (LMWH) is a heterogeneous collection of heparin molecules with a lower average molecular weight compared to unfractionated heparin. Since longer length is necessary to facilitate the interaction between antithrombin III and factor IIa, LMWH is less effective at inhibiting factor IIa (acting mostly via inhibition of Xa).

This topic will review the general principles underlying the therapeutic use of unfractionated and LMW heparins including dosing, monitoring, and reversal of anticoagulation, as well as danaparoid (not available in the United States).

For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery. An ultra-low molecular weight heparin (ultra-LMWH) used to prevent thromboembolism following surgery and extracorporeal clotting during dialysis.

Low Molecular Weight Heparin (LMWH): anticoagulant; potentiates the action of antithrombin III on Xa

Over the past decade newer heparins, the low molecular weight heparin (LMWH) have emerged. They are prepared from unfractionated heparin by enzymatic or depolymerisation methods (Table 1). They can be given safely on out-patient basis without any monitoring and appear to …

Low molecular weight heparin (LMWH) is derived from unfractionated heparin (UFH) by digestion or depolymerization of longer chains of heparin into shorter chains by chemical or enzymatic means. These short strands make LMWH last longer …

Low-molecular-weight heparins (LMWHs) comprise a group in the class of antithrombotic medications, a class headed by unfractionated heparin (UFH). The LMWHs, with mean molecular weights of 4.0-6.0 kD, differ in their individual manufacturing processes, the distribution of their fragment molecular we …